Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 209

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Drug resistance to targeted therapies: Déjà vu all over again

Open access
Groenendijk, Floris H., Bernards, René · 2014 · Molecular Oncology

Abstract

A major limitation of targeted anticancer therapies is intrinsic or acquired resistance. This review emphasizes similarities in the mechanisms of resistance to endocrine therapies in breast cancer and those seen with the new generation of targeted cancer therapeutics. Resistance to single‐agent cancer therapeutics is frequently the result of reactivation of the signaling pathway, indicating that a major limitation of targeted agents lies in their inability to fully block the cancer‐relevant signaling pathway. The development of mechanism‐based combinations of targeted therapies together with non‐invasive molecular disease monitoring is a logical way forward to delay and ultimately overcome drug resistance development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2014.05.004

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 209

Metadata

Authors
Groenendijk, F. H., & Bernards, R.
Venue
Molecular Oncology
Publisher
Wiley
Published
2014-05-21
Volume
8
Issue
6
Pages
1067-1083
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2081886885
Cited by
209
References
39
FWCI
14.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug resistance to targeted therapies: Déjà vu all over again. https://app.cochat.ai/papers/10.1016/j.molonc.2014.05.004
The paper
Groenendijk, F. H., & Bernards, R. (2014). Drug resistance to targeted therapies: Déjà vu all over again. Molecular Oncology. https://doi.org/10.1016/j.molonc.2014.05.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.